Results 11 - 20 of 208 : Previous 1 2 3 4 5 6 7 8 9 Next
AstraZeneca is trying to revive Iressa.
Viagra Stays Behind the Counter
All puns about soft sales and wishing something would go up in this market have been removed from this article.
Double Trouble for AstraZeneca
Generic woes and a miscue in the pipeline, oh my.
The Little Chemotherapy That Could
Slow and steady isn't very exciting.
These drugmakers should be made aware of their fate over the next few weeks.
Merck Could Double Potential Customers
HPV vaccine now recommended for girls and women is also shown to benefit boys and men.
Drug Fuels an Idling Rocket Ship
AstraZeneca needs another FDA approval to really take advantage of cholesterol drug's success.
What's on Deck for AstraZeneca?
The drugmaker increases EPS by cutting costs, but it's the next move that'll count the most.
Deconstructing the All-American Portfolio
Love your country -- but invest in a few others, too.
Merck's a Bloated Garbage Heap of Stale Drugs
Stay away -- really far away.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK